Bristol Myers Squibb announced plans to acquire heart disease treatment company MyoKardia for $13B. The deal is Bristol Myers Squibb’s second large acquisition in the past year, following the $74B acquisition of Celgene which closed last November.
The New Paper
This story is from the October 6, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.
